| A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. | |
| | |
MedLine Citation:
|
PMID: 12270988 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Central venous catheters are frequently needed for the provision of haemodialysis, but their clinical usefulness is severely limited by infectious complications. The risk of such infections can be reduced by topical application of mupirocin to the exit sites of non-cuffed catheters or by the use of tunnelled, cuffed catheters. Whether mupirocin offers any additional protection against infection in patients with tunnelled, cuffed haemodialysis catheters has not been studied. METHODS: An open-label, randomized controlled trial was performed comparing the effect of thrice-weekly exit site application of mupirocin (mupirocin group) vs no ointment (control group) on infection rates and catheter survival in patients receiving haemodialysis via a newly inserted, tunnelled, cuffed central venous catheter. All patients were followed until catheter removal and were monitored for the development of exit site infections and catheter-associated bacteraemias. RESULTS: Fifty patients were enrolled in the study. Both the mupirocin (n=27) and control (n=23) groups were similar at baseline with respect to demographic characteristics, comorbid illnesses and causes of renal failure. Compared with controls, mupirocin-treated patients experienced significantly fewer catheter-related bacteraemias (7 vs 35%, P<0.01) and a longer time to first bacteraemia (log rank score 8.68, P<0.01). The beneficial effect of mupirocin was entirely attributable to a reduction in staphylococcal infection (log rank 10.69, P=0.001) and was still observed when only patients without prior nasal Staphylococcus aureus carriage were included in the analysis (log rank score 6.33, P=0.01). Median catheter survival was also significantly longer in the mupirocin group (108 vs 31 days, log rank score 5.9, P<0.05). Mupirocin use was not associated with any adverse patient effects or the induction of antimicrobial resistance. CONCLUSIONS: Thrice-weekly application of mupirocin to tunnelled, cuffed haemodialysis catheter exit sites is associated with a marked reduction in line-related sepsis and a prolongation of catheter survival. |
| | |
Authors:
|
David Wayne Johnson; Robert MacGinley; Troy David Kay; Carmel Mary Hawley; Scott Bryan Campbell; Nicole Maree Isbel; Peter Hollett |
Related Documents
:
|
3605518 - Vascular complications of intraaortic balloon counterpulsation. 15008718 - Can leakage at the vesico-urethral anastomosis be predicted after radical retropubic pr... 2144708 - Use of a silicone dual-lumen catheter with a dacron cuff as a long-term vascular access... 6760658 - Dacryocystorhinostomy a.m. iliff. a long-term follow-up. 22308098 - Factors influencing survival in patients undergoing palliative bypass for pancreatic ad... 1270498 - The management of thoracic and thoraco-lumbar injuries of the spine with neurological i... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Volume: 17 ISSN: 0931-0509 ISO Abbreviation: Nephrol. Dial. Transplant. Publication Date: 2002 Oct |
Date Detail:
|
Created Date: 2002-09-24 Completed Date: 2003-03-26 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8706402 Medline TA: Nephrol Dial Transplant Country: England |
Other Details:
|
Languages: eng Pagination: 1802-7 Citation Subset: IM |
Affiliation:
|
Department of Renal Medicine, Princess Alexandra Hospital, Brisbane, Australia. david_johnson@health.qld.gov.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Topical Anti-Bacterial Agents / administration & dosage*, economics Bacteremia / epidemiology, etiology Catheterization, Central Venous / instrumentation* Catheters, Indwelling* / adverse effects Drug Costs Equipment Design Humans Infection Control / methods* Mupirocin / administration & dosage*, economics Pseudomonas Infections / epidemiology Renal Dialysis / instrumentation* Staphylococcal Infections / epidemiology |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 12650-69-0/Mupirocin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Aortic valve calcification is an independent factor of left ventricular hypertrophy in patients on m...
Next Document: Gender and age differences in plasma carnitine, muscle strength, and exercise tolerance in haemodial...